Published: Dec 16, 2020
INCHEON, South Korea, Dec. 16, 2020 /PRNewswire/ Samsung Biologics (KRX: 207940.KS) announced John Rim as its President and CEO. The appointment was made effective immediately and formalized via the company s board of directors meeting today.
Prior to being appointed CEO, John served as Executive Vice President at Samsung Biologics for the past three years and was a key senior leadership contributor in driving the company s success through a strong focus on client satisfaction and global business acumen. John was also instrumental in rapidly expanding the manufacturing portfolio across Samsung Biologics and for the continuous operational excellence in Plant 3, the world s largest manufacturing capacity at a single site. As CEO, John will continue to serve on the company s board as an inside director offering his in-depth industry experience and global background.